Stockscreener 앱 받기
1.32
5.60%
0.07
시간 외 거래:
1.31
-0.01
-0.76%
전일 마감가:
$1.25
열려 있는:
$1.25
하루 거래량:
287.47K
Relative Volume:
1.65
시가총액:
$49.69M
수익:
$22.33M
순이익/손실:
$-85.89M
주가수익비율:
-0.5754
EPS:
-2.2942
순현금흐름:
$-89.47M
1주 성능:
+10.92%
1개월 성능:
+3.13%
6개월 성능:
-26.67%
1년 성능:
-21.89%
1일 변동 폭
$1.23
$1.36
1주일 범위
$1.17
$1.36
52주 변동 폭
$1.13
$3.95
Metagenomi Therapeutics Inc Stock (MGX) Company Profile
명칭
Metagenomi Therapeutics Inc
전화
(510) 871-4880
주소
5959 HORTON STREET, EMERYVILLE
Compare MGX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MGX
Metagenomi Therapeutics Inc
|
1.32 | 47.06M | 22.33M | -85.89M | -89.47M | -2.2942 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.94 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Metagenomi Therapeutics Inc Stock (MGX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-05-07 | 개시 | H.C. Wainwright | Buy |
| 2024-05-02 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-03-05 | 개시 | BMO Capital Markets | Outperform |
| 2024-03-05 | 개시 | Chardan Capital Markets | Buy |
| 2024-03-05 | 개시 | JP Morgan | Overweight |
| 2024-03-05 | 개시 | Jefferies | Buy |
| 2024-03-05 | 개시 | TD Cowen | Outperform |
| 2024-03-05 | 개시 | Wells Fargo | Overweight |
모두보기
Metagenomi Therapeutics Inc 주식(MGX)의 최신 뉴스
Metagenomi Therapeutics (MGX) Holds Steady at $1.25 as Stock Consolidates Between Key LevelsSingle Stock ETF - dars.gov.et
Price to sales forward of Metagenomi Therapeutics, Inc. – NASDAQ:MGX - TradingView
Enterprise value to EBIT forward of Metagenomi Therapeutics, Inc. – NASDAQ:MGX - TradingView
Price to book forward of Metagenomi Therapeutics, Inc. – NASDAQ:MGX - TradingView
Price to earnings forward of Metagenomi Therapeutics, Inc. – NASDAQ:MGX - TradingView
Metagenomi Therapeutics, Inc. Actuals & Estimates (NASDAQ:MGX) - TradingView
MGX Forecast — Price Target — Prediction for 2027 - TradingView
Metagenomi Therapeutics (MGX) Edges Lower, Testing Key Support at $1.13Sign of Strength - dars.gov.et
MGX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Metagenomi Therapeutics (MGX) Edges Lower as Stock Tests Key Support ZoneBull Pennant - Město Břeclav
Metagenomi Therapeutics (MGX) director awarded 17,400 stock options at $1.23 - Stock Titan
Metagenomi Therapeutics (MGX) director awarded options on 21,000 shares - Stock Titan
Metagenomi Therapeutics (MGX) director receives 21,000-share stock option grant at $1.23 - Stock Titan
Metagenomi (NASDAQ: MGX) director receives 21,000 stock options at $1.23 strike - Stock Titan
Metagenomi CFO Pamela Wapnick sells $3,746 of company stock - Investing.com UK
Metagenomi CEO Jian Irish sells $4,854 in company stock - Investing.com UK
Metagenomi general counsel Wein sells $724 in common stock - Investing.com UK
Metagenomi CFO Pamela Wapnick sells $3,746 of company stock By Investing.com - Investing.com Australia
[Form 4] Metagenomi Therapeutics, Inc. Insider Trading Activity - Stock Titan
Tax-driven sale as Metagenomi (MGX) director Irish reports 3,737 shares sold - Stock Titan
Metagenomi Announces Board Changes and Shareholder Meeting Results - TipRanks
Metagenomi Therapeutics, Inc. Announces Resignation of Brian C. Thomas, Ph.D. as A Member of the Board, Effective as of June 9, 2026 - marketscreener.com
Brian C. Thomas resigns from Metagenomi board effective June 9, 2026 - TradingView
Metagenomi (NASDAQ: MGX) director exits as shareholders back board - Stock Titan
MGX: Directors and auditor were approved, with no stockholder questions or new nominations - TradingView
MGX: Directors elected, auditor ratified, and all proposals approved with no shareholder questions - TradingView
Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - PR Newswire
Metagenomi Therapeutics (MGX) Slides 2.86% as Stock Tests Key Support LevelsSweep Order Flow - newsline.com
MGX Q1 2026 Earnings: Losses Widen Beyond Expectations as Pre-Revenue Biotech Focuses on PipelineEarnings Forecast Report - thelegaladvocate.com
Metagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare Conference - The Manila Times
MGXMetagenomi Therapeutics Inc Stock Price and Quote - Finviz
MGX Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Advances PipelineEPS Growth Report - The Legal Advocate
MGX Q1 2026 Earnings: Missed Expectations as Pre-Revenue Biotech Advances Gene Editing PipelineEarnings Cycle Outlook - Newser
PRN_FinancialWrapper - FinancialContent
Number of shareholders of Metagenomi Therapeutics, Inc. – NASDAQ:MGX - TradingView
Metagenomi Therapeutics (MGX) price target decreased by 10.71% to 8.50 - MSN
Metagenomi Therapeutics, Inc. (NASDAQ:MGX) Just Reported And Analysts Have Been Cutting Their Estimates - Yahoo Finance
Analysts Have Lowered Expectations For Metagenomi Therapeutics, Inc. (NASDAQ:MGX) After Its Latest Results - simplywall.st
Metagenomi Therapeutics (MGX) reports Q1 loss, misses revenue estimates - MSN
Metagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial Results - The Manila Times
Metagenomi Therapeutics (MGX) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
MSN Money - MSN
Metagenomi Highlights Q1 Progress on MGX-001 Gene Therapy - TipRanks
Metagenomi Therapeutics: Q1 Earnings Snapshot - kare11.com
Metagenomi Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
[10-Q] Metagenomi Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
Metagenomi (NASDAQ: MGX) details Q1 2026 loss, cash runway and MGX-001 IND plans - Stock Titan
Metagenomi gene edit for hemophilia A targets 2027 human trials - Stock Titan
MGX Stock Price, Quote & Chart | METAGENOMI THERAPEUTICS INC (NASDAQ:MGX) - ChartMill
Hemophilia Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - GlobeNewswire Inc.
SEC Form DEF 14A filed by Metagenomi Therapeutics Inc. - Quantisnow
Metagenomi Therapeutics Inc (MGX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Metagenomi Therapeutics Inc 주식 (MGX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Irish Jian | See Remarks |
Jun 05 '26 |
Sale |
1.30 |
3,737 |
4,854 |
377,533 |
| Wein Matthew | See Remarks |
Jun 05 '26 |
Sale |
1.30 |
558 |
725 |
126,491 |
| Wapnick Pamela | Chief Financial Officer |
Mar 05 '26 |
Sale |
1.60 |
1,581 |
2,530 |
187,375 |
| Wein Matthew | See Remarks |
Mar 05 '26 |
Sale |
1.60 |
482 |
771 |
114,549 |
| Irish Jian | Chief Executive Officer |
Mar 05 '26 |
Sale |
1.60 |
1,607 |
2,571 |
333,770 |
| Thomas Brian C. | Director |
Dec 05 '25 |
Sale |
1.77 |
3,830 |
6,786 |
2,510,960 |
| Wein Matthew | See Remarks |
Dec 05 '25 |
Sale |
1.77 |
199 |
353 |
115,031 |
| Wapnick Pamela | Chief Financial Officer |
Dec 05 '25 |
Sale |
1.77 |
1,576 |
2,793 |
188,956 |
| Irish Jian | Chief Executive Officer |
Dec 05 '25 |
Sale |
1.77 |
1,602 |
2,839 |
563,839 |
| Thomas Brian C. | Director |
Sep 05 '25 |
Sale |
1.81 |
2,701 |
4,889 |
2,514,790 |
1.17%
2.48%
자본화:
|
볼륨(24시간):